Content area

|
|

Antivaskulær endotelial vækstfaktor-terapi i onkologisk behandling

Forfatter(e)

Per Pfeiffer1, Torben Frøstrup Hansen2 & Camilla Qvortrup3

1) Onkologisk Afdeling, Odense Universitetshospital, 2) Onkologisk Afdeling, Vejle Sygehus, Sygehus Lillebælt, 3) Onkologisk Klinik, Rigshospitalet

Ugeskr Læger 2020;182:V05200336

Reference: 
UgeskrLæger 2020;182:V05200336
Blad nummer: 
Anti-vascular endothelian growth factor therapy in the field of oncology

Per Pfeiffer, Torben Frøstrup Hansen & Camilla Qvortrup

Ugeskr Læger 2020;182:V05200336

Through many years the ability to suppress angiogenesis has been exploited in the field of oncology. The efficiency is well-documented and the indications are constantly growing, although the impact often is rather limited, as we argue in this review. Recent evidence suggests that inhibition of angiogenesis may be clinically meaningful through several lines of treatment but lack of biomarkers limits an individualised approach. The tumour microenvironment is anti-immune and a combination of anti-angiogenic drugs and immunotherapy has demonstrated impressive results and may alter the therapy in the years to come.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Torben Mahneke | 22/10
1 Kommentar
af Flemming Amter | 19/10
1 Kommentar
af Henrik Dibbern | 18/10
1 Kommentar
af Jens Langhoff-Roos | 17/10
3 kommentarer
af Tomas Christensen Kjær | 16/10
1 Kommentar
af Lars Lindberg Andersen | 15/10
1 Kommentar
af Johan Tommy Robert Wallentin | 14/10
1 Kommentar